In a significant development, early data from the first human stem cell therapy trial show promise in potentially advancing Alzheimer’s care by not only slowing the disease but also aiding in the brain’s self-healing process. The Phase 1 study’s primary goal is to establish a recommended dosage for a potential Phase 2 trial. As Regeneration Biomedical progresses in clinical trials, the therapy may have applications in addressing other conditions like multiple sclerosis, Parkinson’s disease, traumatic brain injury, and amyotrophic lateral sclerosis. For further details, contact Regeneration Biomedical at info@regenerationbiomedical.com, visit their website, or call (877) 240-1660.
Read more from nola.com
